Loading...
XNAS
SAVA
Market cap154mUSD
Dec 05, Last price  
3.19USD
1D
-3.92%
1Q
47.69%
Jan 2017
-20.08%
IPO
-97.71%
Name

Cassava Sciences Inc

Chart & Performance

D1W1MN
XNAS:SAVA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
21.76%
Rev. gr., 5y
%
Revenues
0k
5,080,00053,918,00065,984,00063,725,00020,563,00016,809,00011,484,00010,890,00041,119,00000000000-1,80000
Net income
-24m
L-74.96%
-30,670,0006,188,00020,305,00015,347,000-3,467,000-12,023,000-2,613,000-3,446,00031,544,000-12,386,000-14,145,000-14,850,000-11,911,000-6,557,000-4,245,000-5,854,000-31,802,000-72,472,000-97,217,000-24,342,000
CFO
-117m
L+42.55%
113,232,000-11,827,0002,231,00011,163,000-14,691,000-143,000-260,000-7,171,000-6,947,000-9,549,000-9,053,000-12,234,000-8,237,000-4,770,000-2,514,000-5,382,000-30,196,000-77,514,000-82,025,000-116,929,000
Dividend
Dec 13, 20120.75 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
URL
https://www.cassavasciences.com/
IPO date
Jul 14, 2000
Employees
26
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT